Leading global law firm Baker McKenzie has advised the international Gerresheimer AG ("Gerresheimer") in the acquisition of Sensile Medical AG, Switzerland ("Sensile Medical") under a share purchase agreement. Depending on the achievement of certain contractually specified milestones, the purchase price will be a maximum of EUR 350 million. With this acquisition, Gerresheimer is extending its business model in the direction of an original equipment manufacturer for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers.

"We will accelerate our growth and open new opportunities for business expansion. Sensile Medical is a perfect fit for us with its innovative products and platforms in drug delivery systems, including 'connected' devices", comments Andreas Schütte, Management Board Member of Gerresheimer, the acquisition.

"We are very pleased that we were able to support the successful acquisition of Sensile  Medical," commented Alexander Fischer, Partner in Zurich. "With our cross-border transaction strength we were in the position to support our client efficiently and successfully."

Sensile Medical, a globally leading Swiss medical technology company in the field of large volume injectors, develops innovative drug delivery products and platforms, including digital connected capabilities. It is working successfully with customers on the development of  devices for diabetics and patients with heart complaints. Headquartered in Olten, Switzerland, Sensile Medical employs about 120 employees.

Gerresheimer is a leading global partner to the pharma and healthcare industry. About 10,000 employees worldwide manufacture specialty glass and plastic products. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines.

Baker McKenzie provided comprehensive advice to Gerresheimer with regard to all legal aspects of the transaction. The Baker McKenzie team was led by Alexander Fischer (Partner Zurich), and comprised a team consisting of Barbara Deilmann (Partner, Dusseldorf), Rembert Niebel (Partner, Frankfurt), Christoph  Wolf (Partner, Frankfurt), Katharina Spenner (Partner, Munich), Johannes Teichmann (Partner, Frankfurt), Boris Wenger (Partner, Zurich), Matthias Trautmann (Associate, Zurich), Andreas Jauch (Associate, Frankfurt), Martin Altschwager (Associate, Frankfurt), François Meier (Associate, Zurich), Julia Schieber (Associate, Zurich) and Benedikt Hadorn (Trainee Lawyer, Zurich).

Explore Our Newsroom
See All News